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BACKGROUND: The role of adjuvant chemotherapy after resection of colorectal cancers (CRCs) is well understood for patients with
stage-I or stage-III disease. Its efficacy for those with stage-II disease remains much less clear. Many investigators have sought to
identify prognostic markers that might clarify which patients have the highest risk of recurrence and would, therefore, be most likely
to benefit from chemotherapy. This systematic review examines evidence for the use of peripherally sampled, circulating tumour cells
(CTCs) as such a prognostic marker.
METHODS: A comprehensive literature search was used to identify studies reporting on the significance of CTCs in the postoperative
blood of CRC patients.
RESULTS: Fourteen studies satisfied the inclusion criteria. Six of the nine studies that took blood samples 24h or more postoperatively
found detection of postoperative CTCs to be an independent predictor of cancer recurrence.
CONCLUSION: The presence of CTCs in peripheral blood at least 24h after resection of CRCs is an independent prognostic marker of
recurrence. Further studies are needed to clarify the optimal time point for blood sampling and determine the benefit of
chemotherapy in CTC-positive patients with stage-II disease.
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In modern clinical practice, the accepted treatment for non-
metastatic colorectal cancer (CRC) is tumour resection, with
or without adjuvant chemotherapy depending on tumour stage.
For stage-I cancers, surgical resection is generally curative
without the need for chemotherapy, whereas for stage-III
(node-positive) cancers, adjuvant chemotherapy has been shown
to significantly improve outcomes (1990). For patients with
stage-II (node-negative) cancers, however, the benefits of adjuvant
chemotherapy remain much less clear. For these patients, any
potential benefits are often outweighed by the risks and side-
effects of treatment (Benson et al, 2004). For this reason, the
international QUASAR trial was set up to assess the efficacy of
adjuvant chemotherapy in this patient group. QUASAR concluded
that although adjuvant chemotherapy may improve survival
of patients with stage-II CRC, the absolute improvement in
5-year survival was minimal at only 3.6% (Quasar Collaborative
Group, 2007).
With recurrence rates (RRs) being highly variable for patients
with stage-II disease, investigators have sought to differentiate
between those at high risk and those at low risk of recurrence. By
distinguishing these two subgroups it might be possible to identify
those patients most likely to benefit from adjuvant chemotherapy
and target treatment accordingly. Previously established prognos-
tic markers for cancers at high risk of recurrence include local
tumour extent, regional lymph node metastasis, blood or
lymphatic vessel invasion, residual tumour after curative surgery,
and preoperative elevation of carcinoembryonic antigen (CEA)
(Compton et al, 2000). More recently, molecular detection of
circulating tumour cells (CTCs) has also been investigated as a
potential prognostic marker.
Although previous analyses have demonstrated some prognostic
significance for CTC levels in portal blood sampled intra-
operatively (Katsuno et al, 2008), studies assessing the significance
of preoperative CTC levels have shown little predictive value
in terms of clinical outcome (Wharton et al, 1999; Tsavellas et al,
2001). Other reviews have also assessed the significance of
CTC levels, but these have included relatively few studies with
information on postoperative CTC detection (Sergeant et al, 2008),
and early findings have suggested that this postoperative
detection of CTCs may actually offer greatest prognostic
value. We therefore undertook a systematic review of the evidence
for the use of peri- and postoperative CTC detection in predicting
the outcome following surgical resection of colorectal cancers
(CRCs).
The objectives of this systematic review were (1) to examine
current literature and clarify the prognostic significance of
peripherally sampled CTCs after resection of non-metastatic CRCs;
(2) to identify those markers most likely to be of use in risk-
stratification of CRC patients after potentially curative surgery;
and (3) to identify the most appropriate directions for further
research.
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sMATERIALS AND METHODS
The measurement tool for ‘assessment of multiple systematic
reviews’ (AMSTAR) was used as a reference. This tool consists of
11 items and has good face and content validity for measuring the
methodological quality of systematic reviews (Shea et al, 2007).
Literature search
A literature search was performed using multiple electronic search
engines, including Medline (using PubMed), the Cochrane
Database, Ovid, and Google Scholar. Studies reporting on the
molecular detection of CTCs in postoperative peripheral blood and
its effect on prognosis in CRC (last search date 1st December 2009)
were identified. The following keywords were used for the search:
‘colon’, ‘rectal’, ‘colorectal cancer’, ‘circulating cells’, ‘prognosis’,
‘mRNA’, ‘PCR’, ‘-breast’, ‘-gastric’. The ‘related articles’ function in
PubMed and Google Scholar was also used to identify additional
articles. References of the articles identified were also searched for
by title and then subsequent abstract review.
Eligibility criteria and data extraction
All published studies reporting on the effect of CTCs in
postoperative peripheral blood in CRC on prognosis were
considered. There were no restrictions made on the type of study.
Data were extracted on author, year of publication, study design,
technical aspects of the studies, and outcomes. All data were
extracted by two reviewers (C Kim and G Peach), and any
discrepancies were resolved by consensus from all authors.
Restrictions were made to papers published in the English
language.
Inclusion and exclusion criteria
To be included in the analysis, studies had to (1) include patients
undergoing curative resection of CRC; (2) include peri- or
postoperative CTC detection; (3) report on at least one of the
outcome measures listed in the next section; and (4) include
peripheral blood samples. When two studies were reported by the
same institution and/or authors, both were included in the
analysis.
Studies were excluded from the analysis if (1) outcomes of
interest were not reported; (2) it was impossible to extract or
calculate the necessary data from the published results; (3) it only
reported on the preoperative sampling of peripheral blood; and
(4) only portal and/or mesenteric blood sampling was undertaken.
Outcomes of interest and definitions
The outcomes of interest were any type of prognostic data,
including: disease-free survival (DFS), overall survival (OS), RR,
cancer-specific survival, and odds and hazards ratios (HRs).
Data analysis
Raw data on outcomes of interest were collected and tabulated.
The data were stored on Microsoft Office Excel.
RESULTS
Six hundred and sixty-four articles were identified using the above
keywords. Title and abstract review resulted in the exclusion of 618
articles that did not address the molecular detection of CTCs and
prognosis in CRC. Forty-six references were assessed in full, and a
further 32 studies were excluded (Figure 1). Eight studies were
excluded as they reported only on preoperative blood sampling
(Bessa et al, 2001; Fujita et al, 2001; Wong et al, 2001; Zhang et al,
2005; Douard et al, 2006; Iinuma et al, 2006; Wang et al, 2006;
Friederichs et al, 2007). Nine studies were excluded as they
contained data from which outcomes could not be extracted, of
which four were excluded as they combined positive results of
molecular detection of multiple samples and their effect on
prognosis (Hardingham et al, 2000; Guller et al, 2002; Bosch et al,
2003; Koyanagi et al, 2008), and five were excluded as it was
impossible to extract the data for outcomes of interest (White and
Griffiths, 1976; Funaki et al, 1998; Wyld et al, 1998; Conzelmann
et al, 2005; Wang et al, 2007). Five studies were excluded as they
were reviews or systematic reviews, which did not report on
prognostic outcomes (Tsavellas et al, 2001; Sleijfer et al, 2007;
Riethdorf et al, 2008; Sergeant et al, 2008; Tsouma et al, 2008). Ten
studies were excluded as they did not report on prognostic
outcomes (Denis et al, 1997; Nakamori et al, 1997; Douard et al,
2001; Guadagni et al, 2001; Patel et al, 2002; Silva et al, 2002;
Yokoyama and Yamaue, 2002; Schuster et al, 2004; Yeh et al, 2006;
Lagoudianakis et al, 2009). The outcomes measured in the 14
studies included in this review were too heterogeneous with
regards to the methodology of data collection to allow quantitative
analysis. A systematic review was therefore undertaken.
Study characteristics
The 14 studies included here comprised 1841 patients in total,
with the median number of patients in each study being 99.5
(range 42–438) (Taniguchi et al, 2000; Yamaguchi et al, 2000; Ito
et al, 2002; Bessa et al, 2003; Chen et al, 2004; Sadahiro et al, 2005,
2007; Katsumata et al, 2006; Koch et al, 2006; Lloyd et al, 2006;
Allen-Mersh et al, 2007; Uen et al, 2007, 2008; Wang et al, 2007).
Of the 14 studies included, eight undertook blood sampling peri-
operatively (Taniguchi et al, 2000; Yamaguchi et al, 2000; Ito et al,
2002; Chen et al, 2004; Sadahiro et al, 2005; Katsumata et al, 2006;
Koch et al, 2006; Lloyd et al, 2006), four undertook sampling
approximately 24h after resection (Bessa et al, 2003; Koch et al,
2006; Lloyd et al, 2006; Allen-Mersh et al, 2007), and six undertook
sampling between 24h and 14 days after resection (Chen et al,
46 Articles
searched in full
618 Articles did not relate
to colorectal cancer or
CTC
32 Studies excluded:
- 8 Preoperative only
- 9 Data from which 
outcomes could not be
extracted
- 5 Reviews
- 10 No prognostic end
   point described
664 Articles
identified using
keyword search 
14 Studies
included in the
final analysis
Figure 1 Flow diagram describing the selection of studies included in this
review.
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s2004; Allen-Mersh et al, 2007; Sadahiro et al, 2007; Uen et al, 2007,
2008; Wang et al, 2007).
Tumour stage
The studies examined in this review included patients with various
different stages of disease. Seven investigated the role of CTC in
patients with stage-I to stage-III disease undergoing potentially
curative surgery (Ito et al, 2002; Bessa et al, 2003; Sadahiro et al,
2005, 2007; Allen-Mersh et al, 2007; Wang et al, 2007; Uen et al,
2008); three studied CTC in patients with early CRC (of which two
investigated stage-II disease alone (Koch et al, 2006; Uen et al,
2007) and one investigated stage-I and stage-II disease (Lloyd et al,
2006)); and four papers included patients with stage-I to stage-IV
disease (Taniguchi et al, 2000; Yamaguchi et al, 2000; Chen et al,
2004; Katsumata et al, 2006).
Blood sampling site
Of the 14 studies included in our analysis, 10 involved sampling of
peripheral blood only (Ito et al, 2002; Bessa et al, 2003; Chen et al,
2004; Katsumata et al, 2006; Lloyd et al, 2006; Allen-Mersh et al,
2007; Sadahiro et al, 2007; Uen et al, 2007, 2008; Wang et al,
2007); 1 used peripheral and portal blood samples (Sadahiro et al,
2005); 1 used peripheral and mesenteric samples (Yamaguchi et al,
2000); 1 used peripheral, portal and mesenteric samples (Tani-
guchi et al, 2000); and 1 used samples of central venous blood
(Koch et al, 2006).
CTC detection methods
Thirteen of the 14 included studies used identification of specific
mRNA to detect the presence of CTCs. Eleven of these used reverse
transcriptase-PCR (RT-PCR) to detect tumour cells in the sampled
blood (Taniguchi et al, 2000; Yamaguchi et al, 2000; Ito et al, 2002;
Bessa et al, 2003; Chen et al, 2004; Sadahiro et al, 2005, 2007;
Katsumata et al, 2006; Koch et al, 2006; Allen-Mersh et al, 2007;
Uen et al, 2007) whereas the other two, both from the same unit,
used a membrane array (Wang et al, 2007; Uen et al, 2008). The
remaining study used immunocytochemical staining of circulating
cells after immunomagnetic purification (Lloyd et al, 2006).
Seven of the included studies used a single marker to detect
CTCs, with the chosen marker being CEA mRNA (n¼5),
cytokeratin-20 (CK20), or guanylyl cyclase (GCC) (Taniguchi
et al, 2000; Ito et al, 2002; Bessa et al, 2003; Chen et al, 2004;
Sadahiro et al, 2005, 2007; Koch et al, 2006). The other studies used
multiple markers, with an overall CTC-positive result usually being
determined by detection of more than one marker.
CTC detection rates
There was a mean detection rate of 33.4% (±3.6 s.e.m.). There
were no differences between studies that sampled peri-operatively,
early postoperatively, or late postoperatively, nor were there any
differences between studies that included only early-stage disease,
curative patients only, and patients at all stages. Furthermore,
there was no demonstrable difference in detection rate between
studies that used one, two, or multiple markers. Direct comparison
between the different cellular markers could not be made due to
differences in methodology.
In the three series that only investigated patients with early-
stage disease (i.e., stage-I and/or stage-II) the detection rates were
variable. Koch et al (2006) and Uen et al (2007) reported positivity
rates of 34 and 27%, respectively, whereas the paper by Lloyd et al
(2006) only reported a positive detection rate of less than 5% in
the peripheral blood postoperatively. This paper described the
use of an immunobead technique to purify blood cells, which may
account for any differences.
Patient follow-up
Median follow-up (where stated) ranged from 36 to 68 months. In
the 10 papers that clearly stated the length of follow-up, there was
no identifiable relationship between length of follow-up and the
reported level of CTC significance.
Prognostic influence of CTCs
Peri-operative sampling In the first of the studies to take peri-
operative samples (Table 1), Taniguchi et al (2000) took samples of
both peripheral and portal blood intra-operatively (before mobilisa-
tion of the tumour) and examined them for CEA mRNA using
RT-PCR. Thirty-four percent of patients showed CTC positivity in
peripheral blood and after potentially curative surgery; this group
of patients had a lower DFS (50 vs 74% at 2 years; Po0.01) than
patients without detectable CTC. Conversely, although Sadahiro
et al (2005) also took peripheral blood samples intra-operatively
(pre-resection) and also used a CEA mRNA protocol, they failed to
show any link between CTC positivity and tumour recurrence or
survival. Ito et al also tested for CEA mRNA using RT-PCR, but took
samples immediately after operation. They showed positivity rates
of 37% and showed that those patients who were CTC-positive once
again had reduced DFS (77 vs 92% at 58 months; P¼0.0296).
All other studies that took peri-operative samples used detection
of multiple cellular markers. Yamaguchi et al (2000) showed that
positivity for both CEA and CK20 in blood samples obtained intra-
operatively was associated with a trend towards decreased survival
(60 vs 85% at 1 year), although this was not a statistically
significant difference (P¼0.06). Katsumata et al (2006) chose to
use CEA, CK19, and CK20 mRNA as markers to detect CTCs in
patients with stage-I to stage-IV disease undergoing surgery. They
found both CK19 and CEA positivity to be unrelated to tumour
progression. However, they also showed that whereas CK20
expression had no correlation with local tumour recurrence, it
did correlate with the presence of lymph node metastasis
(P¼0.037), and that 5-year survival in the CK20-positive group
was 65.2 vs 87.5% in the CK-negative group (P¼0.048). None-
theless, CTC positivity as determined by CK20 was not found to be
an independent prognostic marker. This apparent discrepancy is
probably related to CTC positivity reflecting stage (as shown by its
correlation with lymph node metastases) rather than prognosis.
Lloyd et al (2006) used CK20, CEA ephrin-B4, laminin-g2, and
matrilysin mRNA as markers of CTC in peripheral samples taken
preoperatively and intra-operatively (as well as post-operatively –
see below). They did not show any significant correlation between
CTC positivity and survival although mean survival was only 36.5
months in CTC-positive patients as compared with 76 months in
negative patients. It should be noted that although patients in this
study had early disease (stage-I and stage-II only), the number to
test positive for any marker postoperatively was very low (4%)
compared with other papers in this review. Furthermore, none of
the patients were positive for circulating CEA mRNA preopera-
tively, in contrast to other studies discussed here.
Finally, Chen et al (2004) used GCC as a marker of CTCs in
peripheral blood samples taken pre-, intra-, and postoperatively.
Whereas CTC positivity in preoperative and intra-operative
samples did not correlate with prognosis, patients who were CTC
positive in samples taken 14 days postoperatively had significantly
lower DFS and OS (see below).
Early postoperative sampling (0–48h) In the first study that
looked at postoperative sampling (Table 2), Bessa et al (2003)
investigated 66 patients with stage-I to stage-III disease under-
going potentially curative surgery. They used RT-PCR to detect
CEA mRNA in peripheral blood both before and 24h after surgery.
No data were presented in relation to the prognostic significance of
preoperative CTC positivity. Postoperative samples showed a 55%
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positive and negative groups (22 vs 23%, respectively, at 36
months). Similarly, postoperative CTC positivity did not influence
OS. After adjusting for TNM stage, the probability of RRs and OS
rates were also the same in both groups. In addition to taking
preoperative and intra-operative samples (see above), Lloyd et al
(2006) also took peripheral blood samples the morning after
surgery. Unlike Bessa et al, they found that mean survival was
reduced in patients who were CTC-positive at this time point, but
this was not a statistically significant result (mean survival 42.6
months vs 75.9; P¼0.6). However, it is interesting to note that in
this study the postoperative positivity rate was very low (4.2%),
just as it had been in their preoperative samples – even though
high positivity rates might be expected as positivity was defined as
presence of any one of the five markers used.
Allen-Mersh et al (2007) took peripheral samples and used
RT-PCR to detect both CK20 and CEA. Samples were taken
preoperatively, 24h after resection, and at 1 week after operation
(see below). They found no significant difference in outcome
between patients who were CTC-positive preoperatively (as
defined by presence of either marker) and those who were CTC-
negative preoperatively. However, patients who were CTC-positive
24h postoperatively had much poorer DFS (56 vs 90% at 2 years;
Po0.001). These results are supported by the findings of Koch
et al (2006) who took samples of central venous blood at 24h after
resection (as well as peri-operatively – see above). This group
investigated only patients who had stage-II disease and CK20 was
used as the detection marker. They showed that CTC positivity at
24h was associated with reduced 5-year relapse-free survival (70 vs
93%; P¼0.003) and disease-specific survival (77 vs 100%;
P¼0.0006), the latter regardless of whether patients had received
chemotherapy or not. Furthermore, multivariate analysis con-
firmed that identification of CTC tumour cell in the peripheral
blood at 24h after surgery was an independent predictor of relapse
and disease-specific mortality (HR 2.4 (1.3–5.3); P¼0.008, and
HR 6.4 (2.2–34); P¼0.0003, respectively).
Table 1 Characteristics of studies that took blood samples peri-operatively
Outcome result
First
author Year
No.
of
pts
Median
age
(years)
Dukes/
TNM
stage
Blood
sampling
site
Time
sample
taken
Cellular
marker
used
Assay
method
Positivity
rate (%)
Outcome
measured
CTC
+ve
CTC
 ve
Hazard
ratio
(95% CI)
Chen 2004 42 64.2 1–4 P 3 day preop,
peri-op,
14 days post
GCC R — DFS at
36 months
No correl No correl Not stated
Ito 2002 99 — 1–3 P Immed preop,
immed postop
CEA R 50.5 DFS at
58 months
77% 92% Not stated
Katsumata 2006 57 66.1 A, B, C, D P Intra-op CEA
CK19
CK20
R 42.1 DFS at
5 years
65.2% 87.5% 1.63 (CK20)
0.24 (CEA)
(CI not stated)
Koch 2006 90 66 2 CV Peri-op,
24h post
CK20 R 24 DFS at
5 years
72% 90% Not stated
Lloyd 2006 146 74 1, 2 P Preop, intra-op,
24h post
CEA/LAMg2/
CK-20/EphB4/
MAT
R 4 Mean
survival
36.5% 76% Not stated
Sadahiro 2005 100 — 1–3 P, Po Intra-op CEA R 37 DFS No diff No diff 0.24 (0.05, 1.12)
Taniguchi 2000 53 65 A, B, C, D P, Po, mes Intra-op CEA R 34 DFS at
2 years
50% 74% Not stated
Yamaguchi 2000 52 — 1–4 P, mes Preop, intra-op CEA
CK20
R 44.4 1-year
survival
60% 85% 3.38 (periph
CEA+CK20)
(P¼0.353)
Abbreviations: CEA¼carcinoembryonic antigen; CI¼confidence interval; CK19¼cytokeratin-19; CK20¼cytokeratin-20; CTC¼circulating tumour cell; CV¼central venous;
DFS¼disease-free survival; GCC¼guanylyl cyclase-C; hTERT¼human telomerase reverse transciptase; LAMg2¼laminin-5g2; MA¼membrane array; MAT¼matrilysin;
mes¼mesenteric; OS¼overall survival; P¼peripheral; Po¼portal; R¼reverse-transcriptase-PCR.
Table 2 Characteristics of studies that took blood samples 24h after resection
Outcome result
First
author Year
No.
of
pts
Median
age
(years)
Dukes/
TNM
stage
Blood
sampling
site
Time
sample
taken
Cellular
marker
used
Assay
method
Positivity
rate (%)
Outcome
measured
CTC
+ve
CTC
 ve
Hazard
ratio
(95% CI)
Allen-Mersh 2007 147 67.4 A, B, C P Preop,
24h post,
1 week post
CEA
CK20
R 31 DFS at 2 years 56% 90% 8.6 (3.0, 24.3)
Bessa 2003 66 73 1–3 P Preop,
24h post
CEA R 55 Recurrence
at 36 months
22% 23% 1.54 (0.4, 5.0)
Koch 2006 90 66 2 CV Peri-op,
24h post
CK20 R 34 DFS at 5 years 70% 93% 2.4 (1.3, 5.3)
Lloyd 2006 146 74 1, 2 P Preop,
intra-op,
24h post
CEA/LAMg2/
CK-20/EphB4/
MAT
R 4 Mean survival 42.6m 75.9m Not stated
Abbreviations: CEA¼carcinoembryonic antigen; CI¼confidence interval; CK19¼cytokeratin-19; CK20¼cytokeratin-20; CTC¼circulating tumour cell; CV¼central venous;
DFS¼disease free survival; GCC¼guanylyl cyclase-C; hTERT¼human telomerase reverse transciptase; MA¼membrane array; MAT¼matrilysin; LAMg2¼laminin-5g2;
mes¼mesenteric; OS¼overall survival; P¼peripheral; Po¼portal; R¼reverse-transcriptase-PCR.
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A number of studies have also looked at the role of CTCs persisting
more than 48h after surgery (Table 3). Sadahiro et al (2007) used
RT-PCR to detect CEA in peripheral blood samples taken 7–10
days after resection from patients with stage-I to stage-III disease.
The overall rate of postoperative CTC positivity was 22% and CTC-
positive patients showed significantly poorer DFS (51 vs 70% at
5 years; P¼0.007) and OS (65 vs 80% at 5 years; P¼0.04) than
CTC-negative patients. They also found that even among patients
with stage-I disease, RRs were much higher in the CEA mRNA-
positive group (45 vs 22%; P¼0.003). Overall, they were able to
show that CEA mRNA positivity was a significant independent risk
factor for tumour recurrence (RR 2.29 (1.30–4.02)) but not for OS
(RR 1.81 (0.94–3.50)).
Three studies by the same group (Uen et al, 2007, 2008; Wang
et al, 2007) used a membrane array technique to detect multiple
cellular markers. These were CK20, CK19, CEA, and human
telomerase reverse transcriptase (hTERT), and CTC positivity was
defined as presence of all four of these markers. In 194 patients
with stage-II disease undergoing curative surgery, 27.5% were
positive for CTC at least one week after surgery. Almost 85% of
positive patients relapsed whereas only 7.8% of patients negative
for CTC developed recurrence (Uen et al, 2007). Positivity was
shown to be a predictor of relapse (HR 38.6, 13.9–106.9), greater
than T-stage or vascular invasion alone. Similarly, when looking at
all patients undergoing curative surgery (i.e., those with stage-I to
stage-III disease), the same authors again showed that CTC
positivity at 1 week after resection was a prognostic indicator for
recurrence (Po0.001; HR 29.5 (10.3–87.8)). Worse DFS was also
seen in patients with CTC detected postoperatively (Po0.001).
This group also looked at the prognostic effect of CTC detected 4
weeks after surgery using the same membrane array for the
described markers and again showed significant association
between positive CTC and recurrence (HR 18.7 (5.6–112.8)).
Although Chen et al (2004) were unable to show any prognostic
significance of preoperative and intra-operative CTC levels (see
above), they too found late postoperative CTC levels to be a highly
significant indicator of outcome. At 14 days after resection,
patients who were CTC-positive (defined as more than 10
2 CTC per
10
6 nucleated blood cells) had much worse DFS (50 vs 94% at 36
months; P¼0.001) and OS (65 vs 94% at 36 months; P¼0.039)
than those who were CTC-negative. No multivariate analysis was
performed to investigate whether high CTC load was an
independent risk factor.
Allen-Mersh et al (2007) not only took samples preoperatively
and at 24h after operation (see above), but also at 1 week after
resection. At this time point they were unable to show any
difference in prognosis between the CTC-positive and CTC-
negative groups, although this is most probably due to the fact
that there were very few positive results by 1 week after the
operation and this would render any differences between the two
groups statistically insignificant.
DISCUSSION
Staging of disease with Dukes’ or TNM systems is generally used to
help predict recurrence and cancer-specific survival, and identify
patients who may benefit from adjuvant chemotherapy. As
indiscriminate use of chemotherapy for patients with stage-II
disease results in minimal reduction in mortality, identification of
a new prognostic marker may help to determine which patients
would benefit most. Although the majority of the studies included
in this review did not limit their investigations to patients with
stage-II disease, their findings may provide good basis for larger
subsequent trials in this patient group.
The papers presented here did not show peri-operative CTC
levels to be of value in predicting recurrence of CRC. This echoes
the findings of most previous studies looking at preoperative
markers, and whereas Koyanagi et al (2008) found preoperative
detection of CTCs to be an independent prognostic indicator, this
has not been supported by earlier reviews (Wharton et al, 1999;
Tsavellas et al, 2001). Some also noted differences in DFS between
those who were CTC-positive preoperatively and those who were
CTC-negative. This may simply be a reflection of tumour stage
Table 3 Characteristics of studies that took blood samples 448h after resection
Outcome result
First
author Year
No.
of
pts
Median
age
(years)
Dukes/
TNM
stage
Blood
sampling
site
Time
sample
taken
Cellular
marker
used
Assay
method
Positivity
rate (%)
Outcome
measured
CTC
+ve
CTC
 ve
Hazard
ratio
(95% CI)
Allen-Mersh 2007 147 67.4 A,B,C P Preop,
24h post,
1 week post
CEA
CK20
R 40.7 DFS at 2 years No diff No diff 2.91 (1.08, 7.85)
Chen 2004 42 64.2 1–4 P 3 day preop,
peri-op,
14 days post
GCC R 28.6 DFS and (OS)
at 36 months
50% (65%) 94% (94%) Not stated
Sadahiro 2007 200 59 1–3 P 7–10 days
postop
CEA R 22 DFS and (OS)
at 5 years
50% (65%) 94% (94%) 2.29 (1.3, 4.0)
Uen 2007 194 64.9 2 P 41 week
postop
hTERT
CK19
CK20
CEA
R 27.5 Recurrence at
40 months
85% 8% 38.6 (all 4 markers)
(13.9, 106.9)
Uen 2008 438 65.6 1–3 P 1 days preop,
7 days postop
hTERT
CK19
CK20
CEA
MA 31.3 DFS at 5 years 46% 86% 29.5 (all 4 markers)
(10.3, 87.8)
Wang 2007 157 65.8 1–3 P 14 days postop CK19
CK20
CEA
hTERT
MA 57.3 Recurrence
at 36 months
50% 80% 18.5 (all 4 markers)
(5.6, 112.8)
Abbreviations: CEA¼carcinoembryonic antigen; CI¼confidence interval; CK19¼cytokeratin-19; CK20¼cytokeratin-20; CTC¼circulating tumour cell; CV¼central venous;
DFS¼disease-free survival; GCC¼guanylyl cyclase-C; hTERT¼human telomerase reverse transciptase; LAMg2¼laminin-5g2; MA¼membrane array; MAT¼matrilysin;
mes¼mesenteric; OS¼overall survival; P¼peripheral; Po¼portal; R¼reverse-transcriptase-PCR.
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showever, as several of these papers found CTC detection rate to be
dependent on other clinicopathological characteristics (such as
T-stage and lymph node status) that are known to have prognostic
significance.
Six of the nine papers investigating the prognostic role of CTCs
persisting 24h or more after resection found CTC detection to be
an independent predictor of cancer recurrence (Koch et al, 2006;
Allen-Mersh et al, 2007; Sadahiro et al, 2007; Uen et al, 2007, 2008;
Wang et al, 2007). Furthermore, 2 out of 4 papers using early
postoperative sampling showed that CTC detected as early as 24h
postoperatively had significant influence on recurrence (Koch
et al, 2006; Allen-Mersh et al, 2007). Koch et al (2006) also showed
that detection of CTC predicted poorer cancer specific survival.
Unlike Koch et al, Lloyd et al (2006) did not show any relationship
between CTC detection and cancer-specific outcomes. However, it
is interesting to note that although patients in this study had early
disease (stage-I and stage-II only), positivity rate for any of the five
markers used was very low at 4.2% and only 1 out of 113 patients
was positive for circulating CEA mRNA postoperatively. This is in
stark contrast to the other studies, which showed positivity rates
between 22 and 62.9%. Even the studies by Koch et al (2006) and
Uen et al (2007) (which included stage-II patients only) had
positivity rates of 34 and 27.5%, respectively. This may be
explained by the unique immunomagnetic bead methodology that
Lloyd et al used to isolate cells from the blood. With such low rates
of CTC detection, it is highly unlikely that they would have been
able to show a significant association between persisting CTC and
recurrence.
Bessa et al (2003) also failed to show any association between
CTC positivity at 24h and recurrence. However, it is once again
interesting to note that in this study all 28 patients with stage-II
disease received 5-fluorouracil-based adjuvant chemotherapy,
unlike in the studies by Koch et al (2006) and Allen-Mersh et al
(2007), where very few node-negative patients received chemother-
apy (6 and 13% of patients, respectively). This use of chemother-
apy for patients studied by Bessa et al may well have improved the
outcomes of CTC-positive patients with stage-II disease, thereby
masking any potential difference between the two groups.
Furthermore, false-positive and false-negative rates were not
presented in this study and may have influenced their results.
The presence of free CTC is dependent on two processes:
dissemination of cancer cells into the circulation and subsequent
elimination of those cells. Dissemination is thought to occur from
both the primary tumour site and from occult micrometastases,
such as bone marrow, lung, or liver (Pantel and Brakenhoff, 2004).
Surgical manipulation may increase CTC release from the primary
tumour during surgery and make peri- or early postoperative
sampling unreliable. This could explain why peri-operative
sampling has not been shown to be of prognostic significance
(as found in this review) and why few previous studies have been
able to show a role for preoperative CTC. In terms of dissemina-
tion from micrometastases, ongoing release of CTC from these
sites may explain why some patients have persistently high CTC
levels even after resection. This might contribute to the apparent
association between high postoperative CTC levels and poor
prognosis, as high CTC levels could signify more systemically
advanced disease.
Elimination of CTC may also occur by a number of pathways,
including anoikis, mechanical stress, microembolie (Geiger and
Peeper, 2009), and possibly immunological eradication (Johansson
et al, 2008). Although it has previously been suggested that most
CTC are cleared from the circulation within 24h of tumour
resection (Fidler, 1970; Patel et al, 2002), persisting CTCs may have
increased resistance to these degradation processes and therefore
show greater metastatic potential (Song et al, 2001). This would
also be in keeping with the demonstrated correlation between
long-surviving tumour cells and poor prognosis. The significance
of rate of CTC clearance was not generally assessed in detail in the
papers analysed here. Nonetheless, the demonstrated correlation
between persisting CTC positivity and poor prognosis may suggest
that more rapid clearance would be associated with better
prognosis. This is supported in a previous study by Patel et al
(2002), which found that clearance of circulating tumour cells
within 24h of CRC excision was greatest in patients with stage-I
and stage-II disease.
For CTC testing to be used clinically as a prognostic indicator, it
is also important to establish the most reliable time point for blood
sampling. The evidence presented here suggests that when testing
is undertaken at least 24h after surgery, presence of CTC has a
prognostic role: Allen-Mersh et al (2007) and Koch et al (2006)
both showed significance at 24h, with an additional five papers
showing a clear role for testing between 7 and 14 days
postoperatively. However, as direct comparison between these
time points has not yet been undertaken, the optimal timing for
collection of blood samples has yet to be clarified.
Whereas use of multiple cellular markers might be expected to
increase sensitivity and specificity, detection rates were found to
be similar in each series and across all markers. The studies from
Taiwan (Chen et al, 2004; Uen et al, 2007, 2008; Wang et al, 2007)
used an RNA array to detect four different markers, whereas others
showed a prognostic role for CTC using either CEA or CK20
mRNA (or both). A number of additional factors may also affect
the results. These include such things as use of chemotherapy and
differences in RT-PCR methodology, which may vary due to the
method of blood preparation or the time lapse between sampling
and processing. These are not examined in more detail here, as
meta-analysis was not possible due to heterogeneity of existing
data. One might also expect variations in study size to affect the
degree to which CTC significance could be shown. However,
whereas the more highly powered studies did indeed tend to
show greatest significance, studies with relatively few patients
(e.g., Koch et al, 2006) were also able to show prognostic
significance of CTC.
CONCLUSION
The presence of CTCs in peripheral blood at least 24h after
resection of CRCs is an independent prognostic marker of
recurrence. However, further studies are needed to clarify the
optimal time point for postoperative blood sampling, and to
identify the most reliable cellular marker for measurement of CTC
level. The evidence presented here provides a possible basis for
future large-scale, multi-centre trials with more unified methodo-
logy. By including a greater number of patients with stage-II
disease, it may be possible to clarify the significance of CTC within
this subgroup and more accurately identify those patients most
likely to benefit from chemotherapy.
REFERENCES
Allen-Mersh TG, McCullough TK, Patel H, Wharton RQ, Glover C, Jonas SK
(2007) Role of circulating tumour cells in predicting recurrence after
excision of primary colorectal carcinoma. Br J Surg 94: 96–105
Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT,
Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E,
Brouwers M, Charette M, Haller DG (2004) American Society of Clinical
Prognostic significance of CTCs after surgical resection of CRCs
G Peach et al
1332
British Journal of Cancer (2010) 102(9), 1327–1334 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sOncology recommendations on adjuvant chemotherapy for stage II colon
cancer. J Clin Oncol 22: 3408–3419
Bessa X, Elizalde JI, Boix L, Pinol V, Lacy AM, Salo J, Pique JM, Castells A
(2001) Lack of prognostic influence of circulating tumor cells in
peripheral blood of patients with colorectal cancer. Gastroenterology
120: 1084–1092
Bessa X, Pinol V, Castellvi-Bel S, Piazuelo E, Lacy AM, Elizalde JI, Pique JM,
Castells A (2003) Prognostic value of postoperative detection of blood
circulating tumor cells in patients with colorectal cancer operated on for
cure. Ann Surg 237: 368–375
Bosch B, Guller U, Schnider A, Maurer R, Harder F, Metzger U, Marti WR
(2003) Perioperative detection of disseminated tumour cells is an
independent prognostic factor in patients with colorectal cancer. Br J
Surg 90: 882–888
Chen WS, Chung MY, Liu JH, Liu JM, Lin JK (2004) Impact of circulating
free tumor cells in the peripheral blood of colorectal cancer patients
during laparoscopic surgery. World J Surg 28: 552–557
Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR,
Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent
DJ, Taylor CR, Welton M, Willett C (2000) Prognostic factors in
colorectal cancer. College of American Pathologists Consensus Statement
1999. Arch Pathol Lab Med 124: 979–994
Conzelmann M, Linnemann U, Berger MR (2005) Molecular detection of
clinical colorectal cancer metastasis: how should multiple markers be put
to use? Int J Colorectal Dis 20: 137–146
Denis MG, Lipart C, Leborgne J, LeHur PA, Galmiche JP, Denis M, Ruud E,
Truchaud A, Lustenberger P (1997) Detection of disseminated tumor
cells in peripheral blood of colorectal cancer patients. Int J Cancer 74:
540–544
Douard R, Le Maire V, Wind P, Sales JP, Dumas F, Fayemendi L, Landi B,
Benichou J, Cugnenc PH, Gayral F, Loric S (2001) Carcinoembryonic gene
member 2 mRNA expression as a marker to detect circulating enterocytes
in the blood of colorectal cancer patients. Surgery 129: 587–594
Douard R, Wind P, Sales JP, Landi B, Berger A, Benichou J, Gayral F, Loric
S, Cugnenc PH (2006) Long-term prognostic value of detection of
circulating colorectal cancer cells using CGM2 reverse transcriptase-
polymerase chain reaction assay. Surgery 139: 556–562
Fidler IJ (1970) Metastasis: quantitative analysis of distribution and fate of
tumor embolilabeled with 125 I-5-iodo-20-deoxyuridine. J Natl Cancer
Inst 45: 773–782
Friederichs J, Gertler R, Rosenberg R, Dahm M, Nekarda H, Holzmann B,
Siewert JR (2007) Correlation of CK-20-positive cells in peripheral
venous blood with serum CEA levels in patients with colorectal
carcinoma. World J Surg 31: 2329–2334
Fujita S, Kudo N, Akasu T, Moriya Y (2001) Detection of cytokeratin 19 and
20 mRNA in peripheral and mesenteric blood from colorectal cancer
patients and their prognosis. Int J Colorectal Dis 16: 141–146
Funaki NO, Tanaka J, Ohshio G, Onodera H, Maetani S, Imamura M (1998)
Cytokeratin 20 mRNA in peripheral venous blood of colorectal
carcinoma patients. Br J Cancer 77: 1327–1332
Geiger TR, Peeper DS (2009) Metastasis mechanisms. Biochim Biophys Acta
1796: 293–308
Guadagni F, Kantor J, Aloe S, Carone MD, Spila A, D’Alessandro R,
Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P,
Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J
(2001) Detection of blood-borne cells in colorectal cancer patients by
nested reverse transcription-polymerase chain reaction for carcinoem-
bryonic antigen messenger RNA: longitudinal analyses and demonstra-
tion of its potential importance as an adjunct to multiple serum markers.
Cancer Res 61: 2523–2532
Guller U, Zajac P, Schnider A, Bosch B, Vorburger S, Zuber M, Spagnoli GC,
Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR (2002)
Disseminated single tumor cells as detected by real-time quantitative
polymerase chain reaction represent a prognostic factor in patients
undergoing surgery for colorectal cancer. Ann Surg 236: 768–775;
discussion 775–766
Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nuttall JD, Kotasek D,
Dobrovic A (2000) Molecular detection of blood-borne epithelial cells in
colorectal cancer patients and in patients with benign bowel disease. Int J
Cancer 89: 8–13
Iinuma H, Okinaga K, Egami H, Mimori K, Hayashi N, Nishida K, Adachi
M, Mori M, Sasako M (2006) Usefulness and clinical significance of
quantitative real-time RT-PCR to detect isolated tumor cells in the
peripheral blood and tumor drainage blood of patients with colorectal
cancer. Int J Oncol 28: 297–306
Ito S, Nakanishi H, Hirai T, Kato T, Kodera Y, Feng Z, Kasai Y, Ito K,
Akiyama S, Nakao A, Tatematsu M (2002) Quantitative detection of CEA
expressing free tumor cells in the peripheral blood of colorectal cancer
patients during surgery with real-time RT-PCR on a LightCycler. Cancer
Lett 183: 195–203
Johansson M, Denardo DG, Coussens LM (2008) Polarized immune
responses differentially regulate cancer development. Immunol Rev
222: 145–154
Katsumata K, Sumi T, Mori Y, Hisada M, Tsuchida A, Aoki T (2006)
Detection and evaluation of epithelial cells in the blood of colon cancer
patients using RT-PCR. Int J Clin Oncol 11: 385–389
Katsuno H, Zacharakis E, Aziz O, Rao C, Deeba S, Paraskeva P,
Ziprin P, Athanasiou T, Darzi A (2008) Does the presence of circulating
tumor cells in the venous drainage of curative colorectal cancer
resections determine prognosis? A meta-analysis. Ann Surg Oncol 15:
3083–3091
Koch M, Kienle P, Kastrati D, Antolovic D, Schmidt J, Herfarth C, von
Knebel Doeberitz M, Weitz J (2006) Prognostic impact of hematogenous
tumor cell dissemination in patients with stage II colorectal cancer. Int J
Cancer 118: 3072–3077
Koyanagi K, Bilchik AJ, Saha S, Turner RR, Wiese D, McCarter M, Shen P,
Deacon L, Elashoff D, Hoon DS (2008) Prognostic relevance of occult
nodal micrometastases and circulating tumor cells in colorectal cancer in
a prospective multicenter trial. Clin Cancer Res 14: 7391–7396
Lagoudianakis EE, Kataki A, Manouras A, Memos N, Papadima A,
Derventzi A, Zografos G, Papadopoulos S, Katergiannakis V, Konsta-
doulakis MM (2009) Detection of epithelial cells by RT-PCR targeting
CEA, CK20, and TEM-8 in colorectal carcinoma patients using
OncoQuick density gradient centrifugation system. J Surg Res 155:
183–190
Lloyd JM, McIver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE
(2006) Identification of early-stage colorectal cancer patients at risk of
relapse post-resection by immunobead reverse transcription-PCR
analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res
12: 417–423
Nakamori S, Kameyama M, Furukawa H, Takeda O, Sugai S, Imaoka S,
Nakamura Y (1997) Genetic detection of colorectal cancer cells in
circulation and lymph nodes. Dis Colon Rectum 40: S29–S36
NIH consensus conference (1990) Adjuvant therapy for patients with colon
and rectal cancer. JAMA 264: 1444–1450
Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev
Cancer 4: 448–456
Patel H, Le Marer N, Wharton RQ, Khan ZA, Araia R, Glover C, Henry MM,
Allen-Mersh TG (2002) Clearance of circulating tumor cells after excision
of primary colorectal cancer. Ann Surg 235: 226–231
Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK,
Williams NS, Kerr DJ (2007) Adjuvant chemotherapy vs observation
in patients with colorectal cancer: a randomised study. Lancet 370:
2020–2029
Riethdorf S, Wikman H, Pantel K (2008) Review: biological relevance of
disseminated tumor cells in cancer patients. Int J Cancer 123: 1991–2006
Sadahiro S, Suzuki T, Ishikawa K, Saguchi T, Maeda Y, Yasuda S, Makuuchi
H, Yurimoto S, Murayama C (2005) Detection of carcinoembryonic
antigen messenger RNA-expressing cells in portal and peripheral blood
during surgery does not influence relapse in colorectal cancer. Ann Surg
Oncol 12: 988–994
Sadahiro S, Suzuki T, Maeda Y, Yurimoto S, Yasuda S, Makuuchi H, Kamijo
A, Murayama C (2007) Detection of carcinoembryonic antigen
messenger RNA-expressing cells in peripheral blood 7 days after curative
surgery is a novel prognostic factor in colorectal cancer. Ann Surg Oncol
14: 1092–1098
Schuster R, Max N, Mann B, Heufelder K, Thilo F, Grone J, Rokos F, Buhr
HJ, Thiel E, Keilholz U (2004) Quantitative real-time RT-PCR for
detection of disseminated tumor cells in peripheral blood of patients
with colorectal cancer using different mRNA markers. Int J Cancer 108:
219–227
Sergeant G, Penninckx F, Topal B (2008) Quantitative RT-PCR detection of
colorectal tumor cells in peripheral blood – a systematic review. J Surg
Res 150: 144–152
Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter
AC, Tugwell P, Moher D, Bouter LM (2007) Development of AMSTAR: a
measurement tool to assess the methodological quality of systematic
reviews. BMC Med Res Methodol 7: 10
Silva JM, Rodriguez R, Garcia JM, Munoz C, Silva J, Dominguez G,
Provencio M, Espana P, Bonilla F (2002) Detection of epithelial tumour
Prognostic significance of CTCs after surgical resection of CRCs
G Peach et al
1333
British Journal of Cancer (2010) 102(9), 1327–1334 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sRNA in the plasma of colon cancer patients is associated with advanced
stages and circulating tumour cells. Gut 50: 530–534
Sleijfer S, Gratama JW, Sieuwerts AM, Kraan J, Martens JW, Foekens JA
(2007) Circulating tumour cell detection on its way to routine diagnostic
implementation? Eur J Cancer 43: 2645–2650
Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U (2001) Soluble Fas
ligand released by colon adenocarcinoma cells induces host lymphocyte
apoptosis: an active mode of immune evasion in colon cancer. Br J
Cancer 85: 1047–1054
Taniguchi T, Makino M, Suzuki K, Kaibara N (2000) Prognostic
significance of reverse transcriptase-polymerase chain reaction measure-
ment of carcinoembryonic antigen mRNA levels in tumor drainage blood
and peripheral blood of patients with colorectal carcinoma. Cancer 89:
970–976
Tsavellas G, Patel H, Allen-Mersh TG (2001) Detection and clinical
significance of occult tumour cells in colorectal cancer. Br J Surg 88:
1307–1320
Tsouma A, Aggeli C, Pissimissis N, Lembessis P, Zografos GN, Koutsilieris
M (2008) Circulating tumor cells in colorectal cancer: detection methods
and clinical significance. Anticancer Res 28: 3945–3960
Uen YH, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, Chi CW, Wang JY
(2007) Prognostic significance of multiple molecular markers for patients
with stage II colorectal cancer undergoing curative resection. Ann Surg
246: 1040–1046
Uen YH, Lu CY, Tsai HL, Yu FJ, Huang MY, Cheng TL, Lin SR, Wang JY
(2008) Persistent presence of postoperative circulating tumor cells is a
poor prognostic factor for patients with stage I–III colorectal cancer
after curative resection. Ann Surg Oncol 15: 2120–2128
Wang JY, Lin SR, Wu DC, Lu CY, Yu FJ, Hsieh JS, Cheng TL, Koay LB, Uen
YH (2007) Multiple molecular markers as predictors of colorectal cancer
in patients with normal perioperative serum carcinoembryonic antigen
levels. Clin Cancer Res 13: 2406–2413
Wang JY, Wu CH, Lu CY, Hsieh JS, Wu DC, Huang SY, Lin SR (2006)
Molecular detection of circulating tumor cells in the peripheral blood of
patients with colorectal cancer using RT-PCR: significance of the
prediction of postoperative metastasis. World J Surg 30: 1007–1013
Wharton RQ, Jonas SK, Glover C, Khan ZA, Klokouzas A, Quinn H, Henry
M, Allen-Mersh TG (1999) Increased detection of circulating tumor cells
in the blood of colorectal carcinoma patients using two reverse
transcription-PCR assays and multiple blood samples. Clin Cancer Res
5: 4158–4163
White H, Griffiths JD (1976) Circulating malignant cells and fibrinolysis
during resection of colorectal cancer. Proc R Soc Med 69: 467–469
Wong IH, Yeo W, Chan AT, Johnson PJ (2001) Quantitative relationship of
the circulating tumor burden assessed by reverse transcription-
polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood
of colorectal cancer patients with Dukes’ stage, serum carcinoembryonic
antigen level and tumor progression. Cancer Lett 162: 65–73
Wyld DK, Selby P, Perren TJ, Jonas SK, Allen-Mersh TG, Wheeldon J,
Burchill SA (1998) Detection of colorectal cancer cells in peripheral
blood by reverse-transcriptase polymerase chain reaction for cytokeratin
20. Int J Cancer 79: 288–293
Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S (2000) Significant
detection of circulating cancer cells in the blood by reverse transcriptase-
polymerase chain reaction during colorectal cancer resection. Ann Surg
232: 58–65
Yeh CS, Wang JY, Wu CH, Chong IW, Chung FY, Wang YH, Yu YP,
Lin SR (2006) Molecular detection of circulating cancer cells in
the peripheral blood of patients with colorectal cancer by using
membrane array with a multiple mRNA marker panel. Int J Oncol 28:
411–420
Yokoyama S, Yamaue H (2002) Prediction of distant metastasis by using
reverse transcriptase-polymerase chain reaction for epithelial and variant
CD44 mRNA in the peripheral blood of patients with colorectal cancer.
Arch Surg 137: 1069–1073
Zhang XW, Yang HY, Fan P, Yang L, Chen GY (2005) Detection of
micrometastasis in peripheral blood by multi-sampling in patients with
colorectal cancer. World J Gastroenterol 11: 436–438
Prognostic significance of CTCs after surgical resection of CRCs
G Peach et al
1334
British Journal of Cancer (2010) 102(9), 1327–1334 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s